Because sporadic ovarian tumors with hypermethylation of BRCA1 show a BRCA deficiency phenotype and are, therefore, sensitive to drugs that affect impaired homologous recombination [129], methylation analysis might be a useful tool to predict the suitability of corresponding therapy options, i.e., to individualize therapy protocols [130]. The gene discussed is BRCA1; the disease is ovarian neoplasm.